Fig. 7

SDC1 was a potential oncogene in GBM regulated by BRD4. a The Chronos dependency scores for the previously selected genes in GBM cell lines from the CCLE database. The red bar graph represents the chronos dependency score for SDC1. b The correlation between SDC1 and BRD4 expression in GBM patient tissues. Data sourced from CGGA database (mRNAseq_325 dataset). c The expression of SDC1 in clinical GBM patient tissues and normal tissues. Data were sourced from the GEPIA2 database. The red box represented GBM tissue (n = 207), while the gray box represented normal tissue (n = 163). d The expression of SDC1 in GBM patients with different degrees of malignancy. The data was derived from the CGGA database, where CGGA-325 represented data from the mRNAseq_325 dataset, and CGGA-693 represented data from the mRNAseq_693 dataset. Statistical analysis was performed using ANOVA. e Kaplan-Meier analysis examining the correlation between high or low SDC1 expression and the survival probability of patients with both primary and recurrent GBM. The data was derived from the CGGA database, where CGGA-325 represented data from the mRNAseq_325 dataset, and CGGA-693 represented data from the mRNAseq_693 dataset. f Visualization of H3K27Ac modifications near the SDC1 gene in the genome of U87 cells treated with NC (1% DMSO) and MZ1 using IGV software. g, h The mRNA and protein expression levels of SDC1 in tumors from the control group (NC) and the MZ1-treated group, with GAPDH serving as the internal reference. i, j U87, A172, LN229, and U251 cells were treated with NC (1% DMSO) and MZ1 (1 μM for U87, and 0.2 μM for A172, LN229, and U251) for 72 h. The mRNA and protein levels of SDC1 in the cells were detected using RT-qPCR and Western blot, with GAPDH as an internal reference. Data was presented as Mean ± SD. Student’s t-test, *p < 0.05, **p < 0.01; ns, non-significant